A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

Lutzky, Jose; Antonia, Scott; Blake-Haskins, Andy; Li, Xia; Robbins, Paul B.; Shalabi, Aiman; Vasselli, Jim; Ibrahim, Ramy; Khleif, Samir N.; Segal, Neil H.

doi:10.1200/jco.2014.32.15_suppl.3001

Cited by 77 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination with oxaliplatin resulted in complete tumor regression in greater than 50% of treated animals. MEDI4736 is being studied in a phase I trial in advanced solid tumors with expansion cohorts in several responding tumor types including NSCLC and melanoma [81, 86]. It was noted to be well tolerated, with tumor shrinkage detectable in many tumor types.…”

Section: Clinical Trials Of Monoclonal Antibody To Pd-l1mentioning

confidence: 99%

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Ohaegbulam¹,

Assal²,

Lázár‐Molnár³

et al. 2015

Trends in Molecular Medicine

677

510

View full text Add to dashboard Cite

The PD-1 receptor and ligands PD-L1 and PD-L2, members of the CD28 and B7 families, play critical roles in T cell coinhibition and exhaustion. Overexpression of PD-L1 and PD-1 on tumor cells and tumor-infiltrating lymphocytes, respectively, correlates with poor disease outcome in some human cancers. Monoclonal antibodies (mAbs) blockading the PD-1/PD-L1 pathway have been developed for cancer immunotherapy via enhancing T cell functions. Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer, renal cell carcinoma, and bladder cancer. Further studies are needed to dissect mechanisms of variable response rate, to identify biomarkers for clinical response, to develop small molecule inhibitors, and to combine with other therapies.

show abstract

Section: Clinical Trials Of Monoclonal Antibody To Pd-l1mentioning

confidence: 99%

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Ohaegbulam¹,

Assal²,

Lázár‐Molnár³

et al. 2015

Trends in Molecular Medicine

677

510

View full text Add to dashboard Cite

show abstract

“…Novel immunotherapy agents have shown promising activities in advanced urothelial carcinoma (Table 3) [96][97][98][99][100][101][102][103][104]. In 2011, ipilimumab became the first new-generation immunotherapy to be approved by the FDA for melanoma [105].…”

Section: Immunotherapymentioning

confidence: 99%

“…A phase II study with MPDL34280A in advanced urothelial carcinoma is currently recruiting patients [99]. Other PD1 or PD-L1 inhibitors are under development (Table 3) [100][101][102][103][104].…”

Section: Immunotherapymentioning

confidence: 99%

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Ikeda

Hansel

Kurzrock

2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

show abstract

“…Tumor shrinkage appears to be durable. Expansion cohort in NSCLC patients is currently enrolling [91].…”

Section: Medi4736mentioning

confidence: 99%

New strategies to develop new medications for lung cancer and metastasis

Zhao

Adjei

2015

Cancer Metastasis Rev

View full text Add to dashboard Cite

With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.

show abstract

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

Cited by 77 publications

References 0 publications

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

New strategies to develop new medications for lung cancer and metastasis

Contact Info

Product

Resources

About